PBRM1 is inactivated in ∼40% of ccRCC cancers, and these are largely mutually exclusive with p53 mutations, suggesting that in renal cancer, PBRM1 is a key determinant of G2/M DNA damage checkpoint responses. The gene discussed is TP53; the disease is renal carcinoma.